Impact of Omega 3 in Treatment of Inappropriate Sinus Tachycardia

Not Applicable

Completed

• Conditions: Omega 3; Treatment; Inappropriate Sinus Tachycardia
• Interventions: Drug: Omega 3; Other: Standard follow-up

• Registration Number: NCT07138131
• Lead Sponsor: Benha University

Brief Summary

This study aimed to evaluate the effect of omega-3 supplementation on heart rate (HR) control and heart rate variability (HRV) in children with inappropriate sinus tachycardia (IST).

Detailed Description

Inappropriate sinus tachycardia (IST) is a is a common disease of the autonomic nervous system in children in which tachyarrhythmia characterized by a persistent increase in resting sinus rate or disproportionate elevation of heart rate (HR) with minimal physiological effort accompanied by wide ranging symptoms including palpitations, fatigue, presyncope, and exercise intolerance it could cause lead to total disability in severe cases .it also takes a chronic course with Significant adverse effects on quality of life.

Study Timeline

• Study Start: 2023-10-01
• Primary Completion: 2024-09-01
• Study Completion: 2024-09-01
• Status Verified: 2025-08
• Study First Submitted: 2025-08-16
• Study First Submitted QC: 2025-08-16
• Last Update Submitted: 2025-08-16
• Study First Posted: 2025-08-22
• Last Update Posted: 2025-08-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Age from 12 to 16 years.
• Both sexes.
• Patients diagnosed with inappropriate sinus tachycardia (IST).
• Patients with resting heart rate (HR) ≥100 bpm (sitting) and/or 24-hour average HR ≥90.

Exclusion Criteria

• Structural heart disease.
• Patients receiving antiarrhythmic medication.
• Patients with a prior history of arrhythmias such as paroxysmal supraventricular tachycardia (PSVT) or sick sinus syndrome, or orthostatic hypotension.
• Secondary conditions such as anemia, infection, or hyperthyroidism.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group A	Omega 3	Patients received omega-3 supplementation for 3 months.
Group B	Standard follow-up	Patients received standard follow-up without treatment.

Primary Outcome Measures

Name	Time	Method
Heart rate	24 hours post-treatment	Heart rate was recorded at baseline and post-treatment.

Secondary Outcome Measures

Name	Time	Method
Heart rate variability (HRV)	24 hours post-treatment	Heart rate variability (HRV) was recorded at baseline and post-treatment.

Trial Locations

Locations (1)

Benha University; 🇪🇬 Banhā, Al-Qalyubia, Egypt